Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $6.9 million.

  • Anika Therapeutics' Cash from Operations rose 3696.17% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 903.61%. This contributed to the annual value of $5.4 million for FY2024, which is 40218.12% up from last year.
  • As of Q3 2025, Anika Therapeutics' Cash from Operations stood at $6.9 million, which was up 3696.17% from -$189000.0 recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Cash from Operations registered a high of $6.9 million during Q3 2025, and its lowest value of -$8.3 million during Q2 2023.
  • Over the past 5 years, Anika Therapeutics' median Cash from Operations value was $1.6 million (recorded in 2024), while the average stood at $1.2 million.
  • Data for Anika Therapeutics' Cash from Operations shows a peak YoY increase of 65634.1% (in 2023) and a maximum YoY decrease of 36855.57% (in 2023) over the last 5 years.
  • Over the past 5 years, Anika Therapeutics' Cash from Operations (Quarter) stood at $4.5 million in 2021, then plummeted by 89.24% to $481000.0 in 2022, then skyrocketed by 656.34% to $3.6 million in 2023, then tumbled by 56.51% to $1.6 million in 2024, then soared by 334.26% to $6.9 million in 2025.
  • Its Cash from Operations stands at $6.9 million for Q3 2025, versus -$189000.0 for Q2 2025 and -$130000.0 for Q1 2025.